Navigation Links
Tengion Appoints Diane Jorkasky, M.D., to its Board of Directors
Date:8/15/2011

EAST NORRITON, Pa., Aug. 15, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today announced that it has appointed Diane Jorkasky, M.D., who recently joined Endo Pharmaceuticals (Nasdaq: ENDP) as Senior Vice President, Clinical Development and Chief Medical Officer, to its Board of Directors.

Tengion also announced today that Brenda Gavin, D.V.M., Managing Partner at Quaker BioVentures, is stepping down from the Tengion Board of Directors after five years of service. Quaker BioVentures was an early private venture capital investor in Tengion.

"We are pleased to welcome Diane to the Board and look forward to tapping into her extensive clinical development experience as we move our product candidates forward," said David Scheer, Chairman of the Tengion Board of Directors. "We would also like to give our warmest thanks to Brenda for her invaluable counsel and support of Tengion."

Dr. Jorkasky is the enterprise-wide CMO of Endo Pharmaceuticals and a member of the senior R&D management team.  Her responsibilities include chairing Endo's Safety Review Board, managing external partnerships and strategy development in the medical area, and ensuring the safety and ethical conduct of the company's clinical trials.  Prior to joining Endo in 2011, she was Chief Development and Medical Officer at Aileron Therapeutics and previously held a variety of vice president level positions over nearly a decade with Pfizer Global R&D where she led global clinical research science and operational groups.

Dr. Jorkasky began her career at SmithKline Beecham, where she served as Vice President of Clinical Pharmacology for North America. She received her B.A. in Chemistry at the College of Wooster and her M.D. from the University of Pennsylvania and she is board-certified in nephrology, internal medicine and clinical pharmacology.

"I am excited to join the Tengion Board of Directors at this critical juncture for the Company," said Dr. Jorkasky. "There is enormous potential in regenerative medicine and in Tengion's platform and I look forward to the opportunity to work with this seasoned group of scientists and entrepreneurs to help realize that promise."

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
11. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , February 12, 2016 /PRNewswire/ ... nicht anders vermerkt)   http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... des Unternehmens http://www.telestatherapeutics.com abrufbar.    ... (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss des ...
(Date:2/12/2016)... ALISO VIEJO, Calif. , Feb. 12, 2016 /PRNewswire/ ... patient enrollment in a study to evaluate the safety ... specifically for the treatment of ruptured intracranial aneurysms.  Prof ... Bicetre University Hospital, in Paris, France ... the first patient. France ...
(Date:2/12/2016)... 2016  OMS Supply, a large provider of oral ... today the recent launching of their new company website. ... features that enhance the user experience and enable practitioners ... --> --> Despite the ... that started in early 2016, they have already made ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... an Au Pair comes all the way around the world to provide child ... are often worried things won’t go well. More often than not, however, they find out ... the Year winner’s all commented how their Au Pairs have become a part of the ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an ... beginning to account for a significant portion of hernia repairs throughout the United States. ... Beverly Hills Hernia Center notes that this trend has not only been expected, but ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination Drug Development: ... EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination products are ... attention from all stakeholders in the development of new chemical entities. , However, ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
Breaking Medicine News(10 mins):